Compare Shimadzu Corp. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 11.59%
2
Company has very low debt and has enough cash to service the debt requirements
3
Flat results in Jun 25
4
With ROE of 11.01%, it has a expensive valuation with a 2.04 Price to Book Value
5
Majority shareholders : Non Institution
6
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,291,162 Million (Large Cap)
18.00
NA
0.00%
-0.29
11.12%
2.51
Revenue and Profits:
Net Sales:
137,972 Million
(Quarterly Results - Sep 2025)
Net Profit:
15,709 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.3%
0%
3.3%
6 Months
26.82%
0%
26.82%
1 Year
1.42%
0%
1.42%
2 Years
1.56%
0%
1.56%
3 Years
5.81%
0%
5.81%
4 Years
1.86%
0%
1.86%
5 Years
4.25%
0%
4.25%
Shimadzu Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.94%
EBIT Growth (5y)
11.38%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
1.07
Tax Ratio
25.03%
Dividend Payout Ratio
35.96%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
23.39%
ROE (avg)
11.59%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
2.04
EV to EBIT
12.21
EV to EBITDA
9.61
EV to Capital Employed
2.44
EV to Sales
1.62
PEG Ratio
NA
Dividend Yield
0.01%
ROCE (Latest)
19.95%
ROE (Latest)
11.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
137,972.00
134,309.00
2.73%
Operating Profit (PBDIT) excl Other Income
24,290.00
24,094.00
0.81%
Interest
81.00
81.00
Exceptional Items
65.00
46.00
41.30%
Consolidate Net Profit
15,709.00
11,329.00
38.66%
Operating Profit Margin (Excl OI)
140.60%
143.40%
-0.28%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 2.73% vs 3.07% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 38.66% vs -26.67% in Sep 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
539,047.00
511,895.00
5.30%
Operating Profit (PBDIT) excl Other Income
92,402.00
91,861.00
0.59%
Interest
278.00
294.00
-5.44%
Exceptional Items
-1,312.00
145.00
-1,004.83%
Consolidate Net Profit
53,774.00
57,037.00
-5.72%
Operating Profit Margin (Excl OI)
133.10%
142.10%
-0.90%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 5.30% vs 6.15% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -5.72% vs 9.59% in Mar 2024
About Shimadzu Corp. 
Shimadzu Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






